Literature DB >> 29745097

Quality of life after cytoreductive surgery and HIPEC: A single centre prospective study.

Nikolaos Kopanakis1, Eleftherios-Orestis Argyriou, Dimitra Vassiliadou, Christina Sidera, Maria Chionis, John Kyriazanos, Elias Efstathiou, John Spiliotis.   

Abstract

PURPOSE: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has become a crucial method in the management of peritoneal metastasis. This study evaluated the Quality of Life (QoL) post CRS plus HIPEC.
METHODS: 80/95 patients underwent CRS plus HIPEC at the Metaxa Cancer Hospital, Piraeus, Greece from 06/2011 to 06/2015 and completed the colorectal version of the Functional Assessment of Cancer Therapy questionnaire (FACTC, version 4) at 1 week pre-operatively and at 1, 3, 6, 12, 18, 24 months post-operatively. The subscales assessed were the physical, social/family, emotional and functional wellbeing.
RESULTS: In all subscales, fluctuations in the scores indicated a worsening of QoL in the first 3 post-operative months, followed by improvement back to pre-operative levels and even better scores later on. Statistical improvement was proven for the physical and emotional well-being subscales.
CONCLUSIONS: The significant improvement in the physical well-being is attributed to the eradication of symptoms, whereas the relevant improvements in the emotional wellbeing subscale are explained both by the pre-operative desperation of the diagnosis or relapse of malignancy, and the post-operative hopefulness after a successful operation.

Entities:  

Mesh:

Year:  2018        PMID: 29745097

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  3 in total

1.  Cytoreductive Surgery with HIPEC is a Safe and Effective Palliative Option in Chemorefractory Symptomatic Peritoneal Metastasis.

Authors:  Chunmeng Zhang; Asish Patel; Dalton Hegeholz; Krista Brown; Valerie Shostrom; Mallory Pottebaum; Jason M Foster
Journal:  Ann Surg Oncol       Date:  2022-02-24       Impact factor: 5.344

2.  Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Epithelial Ovarian Cancer: A 20-Year Single-Center Experience.

Authors:  Fabio Carboni; Orietta Federici; Isabella Sperduti; Settimio Zazza; Domenico Sergi; Francesco Corona; Mario Valle
Journal:  Cancers (Basel)       Date:  2021-01-29       Impact factor: 6.639

3.  Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Early Results from a Prospective Cohort Study of 115 Patients.

Authors:  Daniel Steffens; Cherry Koh; Nabila Ansari; Michael J Solomon; Kilian Brown; Kate McBride; Jane Young; Christopher J Young; Brendan Moran
Journal:  Ann Surg Oncol       Date:  2020-04-13       Impact factor: 5.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.